EGFRgene copy number as a predictive/biomarker for patients with non-small-cell lung cancer receiving tyrosine kinase inhibitor treatment: a systematic review and meta-analysis

Meta-analysis of Epidermal Growth Factor Receptor and KRAS Gene Status between Primary and Corresponding Metastatic Tumours of Non-small Cell Lung Cancer

(2015) S. Wang et al.   CLINICAL ONCOLOGY

Concurrence of EGFR amplification and sensitizing mutations indicate a better survival benefit from EGFR-TKI therapy in lung adenocarcinoma patients

(2015) Ling Shan et al.   LUNG CANCER

Assessing Bias in Studies of Prognostic Factors

(2013) Jill A. Hayden et al.   ANNALS OF INTERNAL MEDICINE

High EGFR copy number predicts benefits from tyrosine kinase inhibitor treatment for non-small cell lung cancer patients with wild-type EGFR

(2013) Fang Wang et al.   Journal of Translational Medicine

High EGFR Gene Copy Number and Skin Rash as Predictive Markers for EGFR Tyrosine Kinase Inhibitors in Patients with Advanced Squamous Cell Lung Carcinoma

(2012) Y. Lee et al.   CLINICAL CANCER RESEARCH

Global cancer statistics

(2011) Ahmedin Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

EGFR gene copy number as a predictive biomarker for patients receiving tyrosine kinase inhibitor treatment: a systematic review and meta-analysis in non-small-cell lung cancer

(2010) I. J. Dahabreh et al.   ANNALS OF ONCOLOGY

Epidermal Growth Factor Receptor-Related Tumor Markers and Clinical Outcomes with Erlotinib in Non-small Cell Lung Cancer: An Analysis of Patients from German Centers in the TRUST Study

(2010) Claus-Peter Schneider et al.   Journal of Thoracic Oncology

Somatic EGFR Mutation and Gene Copy Gain as Predictive Biomarkers for Response to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer

(2009) I. J. Dahabreh et al.   CLINICAL CANCER RESEARCH

Epidermal growth factor receptor genomic variation in NSCLC patients receiving tyrosine kinase inhibitor therapy: a systematic review and meta-analysis

(2009) Josh John Carlson et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): Study of a comprehensive panel of molecular markers

(2009) Marcello Tiseo et al.   LUNG CANCER

A Phase II Pharmacodynamic Study of Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Previously Treated with Platinum-Based Chemotherapy

(2008) E. Felip et al.   CLINICAL CANCER RESEARCH

Molecular Characteristics of Bronchioloalveolar Carcinoma and Adenocarcinoma, Bronchioloalveolar Carcinoma Subtype, Predict Response to Erlotinib

(2008) Vincent A. Miller et al.   JOURNAL OF CLINICAL ONCOLOGY

Gefitinib Versus Vinorelbine in Chemotherapy-Naïve Elderly Patients With Advanced Non–Small-Cell Lung Cancer (INVITE): A Randomized, Phase II Study

(2008) Lucio Crinò et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular genetics of lung cancer in people who have never smoked

(2008) Janakiraman Subramanian et al.   LANCET ONCOLOGY

Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer

(2008) Helena Linardou et al.   LANCET ONCOLOGY

Gefitinib (ZD1839): Therapy in selected patients with non-small cell lung cancer (NSCLC)?

(2008) Diego Dongiovanni et al.   LUNG CANCER

EGFR Antagonists in Cancer Treatment

(2008) Fortunato Ciardiello et al.   NEW ENGLAND JOURNAL OF MEDICINE